Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chinook Therapeutics, Inc. (formerly Aduro)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological confirmation of recurrent or metastatic HNSCC
Measurable disease as defined by RECIST v1.1
PD-L1 positive
You may not be if
Diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma)
Disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
Prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic HNSCC
Clareo Health | Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
